Vijay Pande, formerly head of a16z's nearly $4 billion biotech practice, has made a notable shift by leaving the large venture fund to co-found VZVC, a much smaller, AI-focused venture firm. Unlike the previous model that involved numerous bets annually, VZVC concentrates on just a handful of high-impact investments, roughly five a year, allowing for deeper involvement and collaboration with founders. Pande’s move reflects his belief that precision and quality in investments trump volume, prioritizing long-term relationships with founders who emphasize integrity and collaboration.

Pande explains that biology is transitioning from a “science of discovery” to an “engineering” approach, largely driven by advances in AI and machine learning. These technologies enable better targeting of drugs to diseases and improved clinical trial designs, though the costs and high failure rates in trials remain significant. He underscores that AI models have the potential to surpass traditional animal models in predicting drug efficacy in humans, and highlights the promise of precision medicine to tailor treatments more effectively to individuals rather than applying broad population averages.

A key challenge in applying AI to biology and medicine is the lack of openly shared datasets. Unlike text or image data that can be widely scraped and distributed, biological data tends to be siloed in proprietary datasets controlled by companies. Pande sees hope in the emergence of shared biological atlases and open-source foundation models that mirror trends in large language models, positing they could democratize access and accelerate innovation in AI-enhanced healthcare.

Reflecting on his past experience at a16z, Pande notes that while technical innovation is critical, success also heavily depends on mastering go-to-market strategies. His new firm’s structure intentionally emphasizes select investments and hands-on support rather than chasing hot deals. This approach aims to foster enduring partnerships with founders who think long-term about winning collectively rather than competing aggressively, marking a thoughtful evolution in biotech venture capital amid an AI-driven transformation of medicine.